Neuropathology of mood disorders: do we see the stigmata of inflammation?

Translational Psychiatry

Volumn 6, Issue 11, 2016, Pages

  Mechawar, N ^a   Savitz, J ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

^c UNIVERSITY OF TULSA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AUTACOID;

ASTROCYTE; BIPOLAR DISORDER; BRAIN; COMPLICATION; HUMAN; IMMUNOLOGY; INFLAMMATION; INTERNEURON; MAJOR DEPRESSION; MENTAL STRESS; METABOLISM; MICROGLIA; NERVE CELL; NEUROLOGIC DISEASE; OLIGODENDROGLIA; PATHOLOGY; PSYCHOLOGY; SUICIDE;

ASTROCYTES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; BIPOLAR DISORDER; BRAIN; DEPRESSIVE DISORDER, MAJOR; GAMMA-AMINOBUTYRIC ACID; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERNEURONS; MICROGLIA; NEURONS; OLIGODENDROGLIA; STRESS, PSYCHOLOGICAL; SUICIDE;

EID: 85019163609     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2016.212     Document Type: Review

References (237)

1. Savitz JB, Price JL, Drevets WC. Neuropathological and neuromorphometric abnormalities in bipolar disorder: view from the medial prefrontal cortical net-work. Neurosci Biobehav Rev 2014; 42: 132–147.
2. Weinberger DR, Radulescu E. Finding the elusive psychiatric "Lesion" with 21st-century neuroanatomy: a note of caution. Am J Psychiatry 2016; 173: 27–33.
3. Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull 2013; 39: 1363–1372.
4. Dargel AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. C-reactive protein alterations in bipolar disorder: a meta-analysis. J Clin Psychiatry 2015; 76: 142–150.
5. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013; 47: 1119–1133.
6. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74: 15–25.
7. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimaki M. Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 2015; 49: 206–215.
8. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446–457.
9. Fiedorowicz JG, Prossin AR, Johnson CP, Christensen GE, Magnotta VA, Wemmie JA. Peripheral inflammation during abnormal mood states in bipolar I disorder. J Affect Disord 2015; 187: 172–178.
10. Munkholm K, Weikop P, Kessing LV, Vinberg M. Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain Behav Immun 2015; 43: 205–213.
11. Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ et al. A dis-criminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 2008; 65: 395–407.
12. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011; 25: 1206–1213.
13. Pandey GN, Ren X, Rizavi HS, Zhang H. Abnormal gene expression of proin-flammatory cytokines and their receptors in the lymphocytes of patients with bipolar disorder. Bipolar Disord 2015; 17: 636–644.
14. Savitz J, Frank MB, Victor T, Bebak M, Marino JH, Bellgowan PS et al. Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional imaging abnormalities. Brain Behav Immun 2013; 31: 161–171.
15. Rizavi HS, Ren X, Zhang H, Bhaumik R, Pandey GN. Abnormal gene expression of proinflammatory cytokines and their membrane-bound receptors in the lym-phocytes of depressed patients. Psychiatry Res 2016; 240: 314–320.
16. Teixeira AL, de Sousa RT, Zanetti MV, Brunoni AR, Busatto GF, Zarate CA, Jr et al. Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. Hum Psychopharmacol 2015; 30: 52–56.
17. Bai YM, Su TP, Li CT, Tsai SJ, Chen MH, Tu PC et al. Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls. Bipolar Disord 2015; 17: 269–277.
18. Morch RH, Dieset I, Faerden A, Hope S, Aas M, Nerhus M et al. Inflammatory evidence for the psychosis continuum model. Psychoneuroendocrinology 2016; 67: 189–197.
19. Wium-Andersen MK, Orsted DD, Nordestgaard BG. Elevated C-reactive protein and late-onset bipolar disorder in 78 809 individuals from the general popula-tion. Br J Psychiatry 2015.
20. Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ, Kotowicz MA et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry 2010; 197: 372–377.
21. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014; 71: 1121–1128.
22. Tully PJ, Baumeister H, Bengel J, Jenkins A, Januszewski A, Martin S et al. The longitudinal association between inflammation and incident depressive symptoms in men: the effects of hs-CRP are independent of abdominal obesity and metabolic disturbances. Physiol Behav 2015; 139: 328–335.
23. Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha ther-apy. Am J Psychiatry 2003; 160: 1342–1345.
24. Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of cytokine-induced depression. Brain Behav Immun 2002; 16: 575–580.
25. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002; 5: 375–388.
26. Capuron L, Miller AH. Cytokines and psychopathology: lessons from inter-feron-alpha. Biol Psychiatry 2004; 56: 819–824.
27. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharma-cological implications. Pharmacol Ther 2011; 130: 226–238.
28. Sandiego CM, Gallezot JD, Pittman B, Nabulsi N, Lim K, Lin SF et al. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci USA 2015; 112: 12468–12473.
29. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010; 68: 748–754.
30. Hannestad J, Subramanyam K, Dellagioia N, Planeta-Wilson B, Weinzimmer D, Pittman B et al. Glucose metabolism in the insula and cingulate is affected by systemic inflammation in humans. J Nucl Med 2012; 53: 601–607.
31. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009; 66: 407–414.
32. Ayorech Z, Tracy DK, Baumeister D, Giaroli G. Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J Affect Disord 2015; 174: 467–478.
33. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I et al. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468–475.
34. Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open 2012; 2: e000643.
35. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31–41.
36. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015; 72: 268–275.
37. Haarman BC, Riemersma-Van der Lek RF, de Groot JC, Ruhe HG, Klein HC, Zandstra TE et al. Neuroinflammation in bipolar disorder-A [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun 2014; 40: 219–225.
38. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2015; 16: 22–34.
39. Harrison NA, Doeller CF, Voon V, Burgess N, Critchley HD. Peripheral inflammation acutely impairs human spatial memory via actions on medial temporal lobe glucose metabolism. Biol Psychiatry 2014; 76: 585–593.
40. Capuron L, Pagnoni G, Drake DF, Woolwine BJ, Spivey JR, Crowe RJ et al. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry 2012; 69: 1044–1053.
41. Felger JC, Li Z, Haroon E, Woolwine BJ, Jung MY, Hu X et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol Psychiatry 2016; 21: 1358.
42. Piani D, Spranger M, Frei K, Schaffner A, Fontana A. Macrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excita-tory amino acids rather than reactive oxygen intermediates and cytokines. Eur J Immunol 1992; 22: 2429–2436.
43. Takaki J, Fujimori K, Miura M, Suzuki T, Sekino Y, Sato K. L-glutamate released from activated microglia downregulates astrocytic L-glutamate transporter expression in neuroinflammation: the 'collusion' hypothesis for increased extracellular L-glutamate concentration in neuroinflammation. J Neuroin-flammation 2012; 9: 275.
44. Evonuk KS, Baker BJ, Doyle RE, Moseley CE, Sestero CM, Johnston BP et al. Inhibition of system Xc(-) transporter attenuates autoimmune inflammatory demyelination. J Immunol 2015; 195: 450–463.
45. Zhao W, Xie W, Le W, Beers DR, He Y, Henkel JS et al. Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J Neuropathol Exp Neurol 2004; 63: 964–977.
46. Tilleux S, Hermans E. Down-regulation of astrocytic GLAST by microglia-related inflammation is abrogated in dibutyryl cAMP-differentiated cultures. J Neurochem 2008; 105: 2224–2236.
47. Kigerl KA, Ankeny DP, Garg SK, Wei P, Guan Z, Lai W et al. System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo. Exp Neurol 2012; 233: 333–341.
48. Dantzer R, Walker AK. Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression? J Neural Transm (Vienna) 2014; 121: 925–932.
49. Fontana AC. Current approaches to enhance glutamate transporter function and expression. J Neurochem 2015; 134: 982–1007.
50. Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36: 426–436.
51. Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 1989; 52: 1319–1328.
52. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983; 219: 316–318.
53. Stone TW. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol 2001; 64: 185–218.
54. Platenik J, Stopka P, Vejrazka M, Stipek S. Quinolinic acid-iron(ii) complexes: slow autoxidation, but enhanced hydroxyl radical production in the Fenton reaction. Free Rad Res 2001; 34: 445–459.
55. Tavares RG, Tasca CI, Santos CE, Wajner M, Souza DO, Dutra-Filho CS. Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. Neuroreport 2000; 11: 249–253.
56. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 2009; 4: e6344.
57. Guillemin GJ, Croitoru-Lamoury J, Dormont D, Armati PJ, Brew BJ. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia 2003; 41: 371–381.
58. Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Traskman-Bendz L, Guil-lemin GJ et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain Behav Immun 2015; 43: 110–117.
59. Savitz J, Dantzer R, Wurfel BE, Victor TA, Ford BN, Bodurka J et al. Neuropro-tective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psy-choneuroendocrinology 2015; 52: 200–211.
60. Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PS et al. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 2015; 40: 463–471.
61. Meier TB, Savitz J, Singh R, Teague TK, Bellgowan PS. Smaller dentate gyrus and CA2 and CA3 volumes are associated with kynurenine metabolites in collegiate football athletes. J Neurotrauma 2016; 33: 1349–1357.
62. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol 2005; 5: 243–251.
63. Cole SW, Levine ME, Arevalo JM, Ma J, Weir DR, Crimmins EM. Loneliness, eudaimonia, and the human conserved transcriptional response to adversity. Psychoneuroendocrinology 2015; 62: 11–17.
64. Cole SW. Human social genomics. PLoS Genet 2014; 10: e1004601.
65. Cole SW, Hawkley LC, Arevalo JM, Cacioppo JT. Transcript origin analysis identifies antigen-presenting cells as primary targets of socially regulated gene expression in leukocytes. Proc Natl Acad Sci USA 2011; 108: 3080–3085.
66. Nagaraja AS, Sadaoui NC, Dorniak PL, Lutgendorf SK, Sood AK. SnapShot: stress and disease. Cell Metab 2016; 23: 388–388 e381.
67. Schillinger JA, Xu F, Sternberg MR, Armstrong GL, Lee FK, Nahmias AJ et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis 2004; 31: 753–760.
68. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis 2007; 7: 71.
69. Glaser R, Kiecolt-Glaser JK, Speicher CE, Holliday JE. Stress, loneliness, and changes in herpesvirus latency. J Behav Med 1985; 8: 249–260.
70. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90: 1279–1283.
71. Appels A, Bar FW, Bar J, Bruggeman C, de Baets M. Inflammation, depressive symptomtology, and coronary artery disease. Psychosom Med 2000; 62: 601–605.
72. Rector JL, Dowd JB, Loerbroks A, Burns VE, Moss PA, Jarczok MN et al. Consistent associations between measures of psychological stress and CMV antibody levels in a large occupational sample. Brain Behav Immun 2014; 38: 133–141.
73. Simanek AM, Cheng C, Yolken R, Uddin M, Galea S, Aiello AE. Herpesviruses, inflammatory markers and incident depression in a longitudinal study of Detroit residents. Psychoneuroendocrinology 2014; 50: 139–148.
74. Yolken RH, Torrey EF. Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol Psychiatry 2008; 13: 470–479.
75. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull 2007; 33: 729–736.
76. Sugden K, Moffitt TE, Pinto L, Poulton R, Williams BS, Caspi A. Is Toxoplasma gondii infection related to brain and behavior impairments in humans? Evidence from a population-representative birth cohort. PLoS One 2016; 11: e0148435.
77. Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, Zimmerman SA et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. J Nerv Ment Dis 2009; 197: 905–908.
78. Duffy AR, Beckie TM, Brenner LA, Beckstead JW, Seyfang A, Postolache TT et al. Relationship between Toxoplasma gondii and mood disturbance in women veterans. Mil Med 2015; 180: 621–625.
79. Dickerson F, Stallings C, Origoni A, Vaughan C, Katsafanas E, Khushalani S et al. Antibodies to Toxoplasma gondii in individuals with mania. Bipolar Disord 2014; 16: 129–136.
80. Carruthers VB, Suzuki Y. Effects of Toxoplasma gondii infection on the brain. Schizophr Bull 2007; 33: 745–751.
81. Notarangelo FM, Wilson EH, Horning KJ, Thomas MA, Harris TH, Fang Q et al. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. Schizophr Res 2014; 152: 261–267.
82. Floreani A, Leung PS, Gershwin ME. Environmental basis of autoimmunity. Clin Rev Allergy Immunol 2016; 50: 287–300.
83. Korczak DJ, Pereira S, Koulajian K, Matejcek A, Giacca A. Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link. Diabetologia 2011; 54: 2483–2493.
84. Vonk R, van der Schot AC, Kahn RS, Nolen WA, Drexhage HA. Is autoimmune thyroiditis part of the genetic vulnerability (or an endophenotype) for bipolar disorder? Biol Psychiatry 2007; 62: 135–140.
85. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 2010; 12: 638–646.
86. Kosmidis MH, Bozikas VP, Giannouli V, Karavatos A, Fokas K. Familial comorbidity of bipolar disorder and multiple sclerosis: genetic susceptibility, coexistence or causal relationship? Behav Neurol 2012; 25: 341–349.
87. Davison K. Autoimmunity in psychiatry. Br J Psychiatry 2012; 200: 353–355.
88. Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 2013; 70: 812–820.
89. Pop VJ, Maartens LH, Leusink G, van Son MJ, Knottnerus AA, Ward AM et al. Are autoimmune thyroid dysfunction and depression related? J Clin Endocrinol Metab 1998; 83: 3194–3197.
90. Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002; 51: 305–311.
91. Ching KH, Burbelo PD, Carlson PJ, Drevets WC, Iadarola MJ. High levels of Anti-GAD65 and Anti-Ro52 autoantibodies in a patient with major depressive disorder showing psychomotor disturbance. Journal of neuroimmunology 2010; 222: 87–89.
92. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63–74.
93. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor ence-phalitis. JAMA Neurol 2013; 70: 1133–1139.
94. Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor ence-phalitis. JAMA Psychiatry 2013; 70: 271–278.
95. Bergink V, Armangue T, Titulaer MJ, Markx S, Dalmau J, Kushner SA. Autoimmune encephalitis in postpartum psychosis. Am J Psychiatry 2015; 172: 901–908.
96. Lennox BR, Coles AJ, Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry 2012; 200: 92–94.
97. Oberheim NA, Wang X, Goldman S, Nedergaard M. Astrocytic complexity distinguishes the human brain. Trends Neurosci 2006; 29: 547–553.
98. Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F et al. Uniquely hominid features of adult human astrocytes. J Neurosci 2009; 29: 3276–3287.
99. Torres-Platas SG, Nagy C, Wakid M, Turecki G, Mechawar N. Glial fibrillary acidic protein is differentially expressed across cortical and subcortical regions in healthy brains and downregulated in the thalamus and caudate nucleus of depressed suicides. Mol Psychiatry 2016; 21: 509–515.
100. Sosunov AA, Wu X, Tsankova NM, Guilfoyle E, McKhann GM 2nd, Goldman JE. Phenotypic heterogeneity and plasticity of isocortical and hippocampal astro-cytes in the human brain. J Neurosci 2014; 34: 2285–2298.
101. Tonelli LH, Stiller J, Rujescu D, Giegling I, Schneider B, Maurer K et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psy-chiatr Scand 2008; 117: 198–206.
102. Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4 in the brain: a cytokine to remember. J Immunol 2012; 189: 4213–4219.
103. Yang MS, Ji KA, Jeon SB, Jin BK, Kim SU, Jou I et al. Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia. J Immunol 2006; 177: 1323–1329.
104. Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res 2012; 46: 57–63.
105. Pandey GN, Rizavi HS, Ren X, Bhaumik R, Dwivedi Y. Toll-like receptors in the depressed and suicide brain. J Psychiatr Res 2014; 53: 62–68.
106. Dean B, Tawadros N, Scarr E, Gibbons AS. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord 2010; 120: 245–248.
107. Dean B, Gibbons AS, Tawadros N, Brooks L, Everall IP, Scarr E. Different changes in cortical tumor necrosis factor-alpha-related pathways in schizophrenia and mood disorders. Mol Psychiatry 2013; 18: 767–773.
108. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroin-flammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010; 15: 384–392.
109. Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011; 16: 751–762.
110. Elashoff M, Higgs BW, Yolken RH, Knable MB, Weis S, Webster MJ et al. Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci 2007; 31: 221–243.
111. Fillman SG, Sinclair D, Fung SJ, Webster MJ, Shannon Weickert C. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl Psychiatry 2014; 4: e365.
112. Clark SM, Pocivavsek A, Nicholson JD, Notarangelo FM, Langenberg P, McMahon RP et al. Reduced kynurenine pathway metabolism and cytokine expression in the prefrontal cortex of depressed individuals. J Psychiatry Neurosci 2016; 41: 150226.
113. Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. PLoS Biol 2010; 8: e1000527.
114. Guillemin GJ, Microglia Brew BJ. macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 2004; 75: 388–397.
115. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 2011; 91: 461–553.
116. Torres-Platas SG, Comeau S, Rachalski A, Bo GD, Cruceanu C, Turecki G et al. Morphometric characterization of microglial phenotypes in human cerebral cortex. J Neuroinflammation 2014; 11: 12.
117. Galea I, Felton LM, Waters S, van Rooijen N, Perry VH, Newman TA. Immune-to-brain signalling: the role of cerebral CD163-positive macrophages. Neurosci Lett 2008; 448: 41–46.
118. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008; 42: 151–157.
119. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutama-tergic neurotransmission? J Neuroinflammation 2011; 8: 94.
120. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. Brain Behav Immun 2014; 42: 50–59.
121. Wohleb ES, Powell ND, Godbout JP, Sheridan JF. Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. J Neurosci 2013; 33: 13820–13833.
122. Espey MG, Chernyshev ON, Reinhard JF Jr, Namboodiri MA, Colton CA. Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 1997; 8: 431–434.
123. Schnieder TP, Trencevska I, Rosoklija G, Stankov A, Mann JJ, Smiley J et al. Microglia of prefrontal white matter in suicide. J Neuropathol Exp Neurol 2014; 73: 880–890.
124. Haroon E, Woolwine BJ, Chen X, Pace TW, Parekh S, Spivey JR et al. IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 2014; 39: 1777–1785.
125. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007; 62: 1310–1316.
126. Yuksel C, Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010; 68: 785–794.
127. Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord 2012; 14: 478–487.
128. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005; 10: 900–919.
129. Rajkowska G, Stockmeier CA. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 2013; 14: 1225–1236.
130. Torres-Platas SG, Hercher C, Davoli MA, Maussion G, Labonte B, Turecki G et al. Astrocytic hypertrophy in anterior cingulate white matter of depressed suicides. Neuropsychopharmacology 2011; 36: 2650–2658.
131. Webster MJ, O'Grady J, Kleinman JE, Weickert CS. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005; 133: 453–461.
132. Cobb JA, O'Neill K, Milner J, Mahajan GJ, Lawrence TJ, May WL et al. Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. Neuroscience 2016; 316: 209–220.
133. Ernst C, Deleva V, Deng X, Sequeira A, Pomarenski A, Klempan T et al. Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers. Arch Gen Psychiatry 2009; 66: 22–32.
134. Ernst C, Nagy C, Kim S, Yang JP, Deng X, Hellstrom IC et al. Dysfunction of astrocyte connexins 30 and 43 in dorsal lateral prefrontal cortex of suicide completers. Biol Psychiatry 2011; 70: 312–319.
135. Nagy C, Suderman M, Yang J, Szyf M, Mechawar N, Ernst C et al. Astrocytic abnormalities and global DNA methylation patterns in depression and suicide. Mol Psychiatry 2015; 20: 320–328.
136. Tynan RJ, Beynon SB, Hinwood M, Johnson SJ, Nilsson M, Woods JJ et al. Chronic stress-induced disruption of the astrocyte network is driven by structural atro-phy and not loss of astrocytes. Acta Neuropathol 2013; 126: 75–91.
137. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 2006; 98: 641–653.
138. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005; 102: 15653–15658.
139. Bernard R, Kerman IA, Thompson RC, Jones EG, Bunney WE, Barchas JD et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry 2011; 16: 634–646.
140. Medina A, Burke S, Thompson RC, Bunney W Jr, Myers RM, Schatzberg A et al. Glutamate transporters: a key piece in the glutamate puzzle of major depressive disorder. J Psychiatr Res 2013; 47: 1150–1156.
141. Chandley MJ, Szebeni K, Szebeni A, Crawford J, Stockmeier CA, Turecki G et al. Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder. J Psychiatry Neurosci 2013; 38: 276–284.
142. Rao JS, Kellom M, Reese EA, Rapoport SI, Kim HW. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizo-phrenic patients. J Affect Disord 2012; 136: 63–71.
143. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161: 171–174.
144. McCullumsmith RE, Meador-Woodruff JH. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 2002; 26: 368–375.
145. Myles-Worsley M, Tiobech J, Browning SR, Korn J, Goodman S, Gentile K et al. Deletion at the SLC1A1 glutamate transporter gene co-segregates with schizophrenia and bipolar schizoaffective disorder in a 5-generation family. Am J Med Genet B Neuropsychiatr Genet 2013; 162B: 87–95.
146. Fiorentino A, Sharp SI, McQuillin A. Association of rare variation in the glutamate receptor gene SLC1A2 with susceptibility to bipolar disorder and schizophrenia. Eur J Hum Genet 2015; 23: 1200–1206.
147. Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S et al. Ser-oprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 2014; 76: 82–94.
148. Iorio R. Treatment-resistant depression and aquaporin-4 autoantibodies: is there a link? Biol Psychiatry 2015; 78: e1–e2.
149. Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008; 205: 2473–2481.
150. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J 2012; 279: 1356–1365.
151. Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009; 4: e6585.
152. Deng W. Neurobiology of injury to the developing brain. Nat Rev Neurol 2010; 6: 328–336.
153. Juurlink BH. Response of glial cells to ischemia: roles of reactive oxygen species and glutathione. Neurosci Biobehav Rev 1997; 21: 151–166.
154. Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE et al. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 2002; 22: 2478–2486.
155. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA 2003; 100: 8514–8519.
156. Moyon S, Dubessy AL, Aigrot MS, Trotter M, Huang JK, Dauphinot L et al. Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration. J Neurosci 2015; 35: 4–20.
157. Fernandez-Castaneda A, Gaultier A. Adult oligodendrocyte progenitor cells-Multifaceted regulators of the CNS in health and disease. Brain Behav Immun 2016; 57: 1–7.
158. Nosarti C, Reichenberg A, Murray RM, Cnattingius S, Lambe MP, Yin L et al. Preterm birth and psychiatric disorders in young adult life. Arch Gen Psychiatry 2012; 69: E1–E8.
159. Edgar N, Sibille E. A putative functional role for oligodendrocytes in mood regulation. Transl Psychiatry 2012; 2: e109.
160. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290–13295.
161. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58: 545–553.
162. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002; 12: 386–394.
163. Hercher C, Parent M, Flores C, Canetti L, Turecki G, Mechawar N. Alcohol dependence-related increase of glial cell density in the anterior cingulate cortex of suicide completers. J Psychiatry Neurosci 2009; 34: 281–288.
164. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001; 49: 741–752.
165. Bowley MP, Drevets WC, Ongur D, Price JL. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002; 52: 404–412.
166. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligoden-drocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007; 94: 273–280.
167. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004; 67: 269–275.
168. Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004; 55: 563–569.
169. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001; 55: 597–610.
170. Chambers JS, Perrone-Bizzozero NI. Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. Neurochem Res 2004; 29: 2293–2302.
171. Regenold WT, Phatak P, Marano CM, Gearhart L, Viens CH, Hisley KC. Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizo-phrenia, bipolar disorder, and unipolar major depression. Psychiatry Res 2007; 151: 179–188.
172. Hayashi Y, Nihonmatsu-Kikuchi N, Yu X, Ishimoto K, Hisanaga SI, Tatebayashi Y. A novel, rapid, quantitative cell-counting method reveals oligodendroglial reduction in the frontopolar cortex in major depressive disorder. Mol Psychiatry 2011; 16: 1155–1158.
173. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798–805.
174. Myung W, Han CE, Fava M, Mischoulon D, Papakostas GI, Heo JY et al. Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder. Transl Psychiatry 2016; 6: e835.
175. Houenou J, Wessa M, Douaud G, Leboyer M, Chanraud S, Perrin M et al. Increased white matter connectivity in euthymic bipolar patients: diffusion tensor tractography between the subgenual cingulate and the amygdalo-hippocampal complex. Mol Psychiatry 2007; 12: 1001–1010.
176. McIntosh AM, Maniega SM, Lymer GK, McKirdy J, Hall J, Sussmann JE et al. White matter tractography in bipolar disorder and schizophrenia. Biol Psychiatry 2008; 64: 1088–1092.
177. Sussmann JE, Lymer GK, McKirdy J, Moorhead TW, Munoz Maniega S, Job D et al. White matter abnormalities in bipolar disorder and schizophrenia detected using diffusion tensor magnetic resonance imaging. Bipolar Disord 2009; 11: 11–18.
178. Benedetti F, Poletti S, Hoogenboezem TA, Mazza E, Ambree O, de Wit H et al. Inflammatory cytokines influence measures of white matter integrity in bipolar disorder. J Affect Disord 2016; 202: 1–9.
179. Molina V, Sanchez J, Sanz J, Reig S, Benito C, Leal I et al. Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder. Eur Psychiatry 2007; 22: 505–512.
180. Chang K, Adleman N, Dienes K, Barnea-Goraly N, Reiss A, Ketter T. Decreased N-acetylaspartate in children with familial bipolar disorder. Biol Psychiatry 2003; 53: 1059–1065.
181. Sassi RB, Stanley JA, Axelson D, Brambilla P, Nicoletti MA, Keshavan MS et al. Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients. Am J Psychiatry 2005; 162: 2109–2115.
182. Zhang J, Narr KL, Woods RP, Phillips OR, Alger JR, Espinoza RT. Glutamate normalization with ECT treatment response in major depression. Mol Psychiatry 2013; 18: 268–270.
183. Birey F, Kloc M, Chavali M, Hussein I, Wilson M, Christoffel DJ et al. Genetic and Stress-Induced Loss of NG2 Glia Triggers Emergence of Depressive-like Behaviors through Reduced Secretion of FGF2. Neuron 2015; 88: 941–956.
184. Stadelmann C, Wegner C, Bruck W. Inflammation, demyelination, and degen-eration-recent insights from MS pathology. Biochim Biophys Acta 2011; 1812: 275–282.
185. Politte LC, Huffman JC, Stern TA. Neuropsychiatric manifestations of multiple sclerosis. Prim Care Companion J Clin Psychiatry 2008; 10: 318–324.
186. Johnson B, Nichols S. Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: Case report and literature review. Palliat Support Care 2015; 13: 1797–1801.
187. Ahmed A, Simmons Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag 2013; 9: 483–489.
188. Ghasemi M, Phillips C, Trillo L, De Miguel Z, Das D, Salehi A. The role of NMDA receptors in the pathophysiology and treatment of mood disorders. Neurosci Biobehav Rev 2014; 47: 336–358.
189. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensiti-zation: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 2008; 28: 5189–5194.
190. Zhang RX, Liu B, Li A, Wang L, Ren K, Qiao JT et al. Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phos-phorylation. Neuroscience 2008; 154: 1533–1538.
191. Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, Bartfai T et al. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain 2008; 131(Pt 12): 3256–3265.
192. Kessing CF, Tyor WR. Interferon-alpha induces neurotoxicity through activation of the type I receptor and the GluN2A subunit of the NMDA receptor. J Interferon Cytokine Res 2015; 35: 317–324.
193. Di Filippo M, Tozzi A, Arcangeli S, de Iure A, Durante V, Di Gregorio M et al. Interferon-beta1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors. Neuropharmacology 2016; 100: 98–105.
194. Forrest CM, Khalil OS, Pisar M, Darlington LG, Stone TW. Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus. Brain Res 2013; 1504: 1–15.
195. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 70–75.
196. Karolewicz B, Stockmeier CA, Ordway GA. Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharma-cology 2005; 30: 1557–1567.
197. Karolewicz B, Szebeni K, Gilmore T, Maciag D, Stockmeier CA, Ordway GA. Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol 2009; 12: 143–153.
198. Gray AL, Hyde TM, Deep-Soboslay A, Kleinman JE, Sodhi MS. Sex differences in glutamate receptor gene expression in major depression and suicide. Mol Psychiatry 2015; 20: 1057–1068.
199. Scarr E, Pavey G, Sundram S, MacKinnon A, Dean B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord 2003; 5: 257–264.
200. McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 2007; 1127: 108–118.
201. Benes FM, Lim B, Matzilevich D, Subburaju S, Walsh JP. Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolars. Proc Natl Acad Sci USA 2008; 105: 20935–20940.
202. Beneyto M, Meador-Woodruff JH. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008; 33: 2175–2186.
203. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depres-sive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013; 38: 1609–1616.
204. Neale SA, Copeland CS, Uebele VN, Thomson FJ, Salt TE. Modulation of hippo-campal synaptic transmission by the kynurenine pathway member xanthurenic acid and other VGLUT inhibitors. Neuropsychopharmacology 2013; 38: 1060–1067.
205. Daniels RW, Collins CA, Chen K, Gelfand MV, Featherstone DE, DiAntonio A. A single vesicular glutamate transporter is sufficient to fill a synaptic vesicle. Neuron 2006; 49: 11–16.
206. Uezato A, Meador-Woodruff JH, McCullumsmith RE. Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive dis-order, bipolar disorder, and schizophrenia. Bipolar Disord 2009; 11: 711–725.
207. Vigneault E, Poirel O, Riad M, Prud'homme J, Dumas S, Turecki G et al. Distribution of vesicular glutamate transporters in the human brain. Front Neuro-anatomy 2015; 9: 23.
208. Eastwood SL, Harrison PJ. Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 2010; 67: 1010–1016.
209. Gilabert-Juan J, Varea E, Guirado R, Blasco-Ibanez JM, Crespo C, Nacher J. Alterations in the expression of PSA-NCAM and synaptic proteins in the dorsolateral prefrontal cortex of psychiatric disorder patients. Neurosci Lett 2012; 530: 97–102.
210. Woo TU, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2004; 61: 649–657.
211. Woo TU, Shrestha K, Amstrong C, Minns MM, Walsh JP, Benes FM. Differential alterations of kainate receptor subunits in inhibitory interneurons in the anterior cingulate cortex in schizophrenia and bipolar disorder. Schizophr Res 2007; 96: 46–61.
212. Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 2002; 51: 377–386.
213. Woo TU, Kim AM, Viscidi E. Disease-specific alterations in glutamatergic neuro-transmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res 2008; 1218: 267–277.
214. Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000; 57: 1061–1069.
215. Veldic M, Guidotti A, Maloku E, Davis JM, Costa E. In psychosis, cortical inter-neurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci USA 2005; 102: 2152–2157.
216. Thompson M, Weickert CS, Wyatt E, Webster MJ. Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J Psychiatr Res 2009; 43: 970–977.
217. Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 2002; 59: 521–529.
218. Kim S, Webster MJ. Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 2010; 15: 326–336.
219. Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the pre-frontal cortex in major depression. Neuropsychopharmacology 2007; 32: 471–482.
220. Maciag D, Hughes J, O'Dwyer G, Pride Y, Stockmeier CA, Sanacora G et al. Reduced density of calbindin immunoreactive GABAergic neurons in the occi-pital cortex in major depression: relevance to neuroimaging studies. Biol Psychiatry 2010; 67: 465–470.
221. Smiley JF, Hackett TA, Bleiwas C, Petkova E, Stankov A, Mann JJ et al. Reduced GABA neuron density in auditory cerebral cortex of subjects with major depressive disorder. J Chem Neuroanatomy 2015; 76: 108–121.
222. Gonzalez-Burgos G, Cho RY, Lewis DA. Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry 2015; 77: 1031–1040.
223. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 2008; 34: 944–961.
224. Yamamoto J, Suh J, Takeuchi D, Tonegawa S. Successful execution of working memory linked to synchronized high-frequency gamma oscillations. Cell 2014; 157: 845–857.
225. Kimoto S, Zaki MM, Bazmi HH, Lewis DA. Altered markers of cortical gamma-aminobutyric acid neuronal activity in schizophrenia: role of the NARP gene. JAMA Psychiatry 2015; 72: 747–756.
226. Crowley T, Cryan JF, Downer EJ, O'Leary OF. Inhibiting neuroinflammation: the role and therapeutic potential of GABA in neuro-immune interactions. Brain Behav Immun 2016; 54: 260–277.
227. Clements RJ, McDonough J, Freeman EJ. Distribution of parvalbumin and cal-retinin immunoreactive interneurons in motor cortex from multiple sclerosis post-mortem tissue. Exp Brain Res 2008; 187: 459–465.
228. Wieck A, Andersen SL, Brenhouse HC. Evidence for a neuroinflammatory mechanism in delayed effects of early life adversity in rats: relationship to cortical NMDA receptor expression. Brain Behav Immun 2013; 28: 218–226.
229. Giovanoli S, Weber L, Meyer U. Single and combined effects of prenatal immune activation and peripubertal stress on parvalbumin and reelin expression in the hippocampal formation. Brain Behav Immun 2014; 40: 48–54.
230. Brooks JM, Carrillo GL, Su J, Lindsay DS, Fox MA, Blader IJ. Toxoplasma gondii infections alter GABAergic synapses and signaling in the central nervous system. Mbio 2015; 6: e01428–15.
231. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009; 9: 429–439.
232. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Ann Rev Immunol 2009; 27: 119–145.
233. Loane DJ, Kumar A. Microglia in the TBI brain: the good, the bad, and the dysregulated. Exp Neurol 2015; 275: 316–327.
234. Gras G, Porcheray F, Samah B, Leone C. The glutamate-glutamine cycle as an indu-cible, protective face of macrophage activation. J Leukoc Biol 2006; 80: 1067–1075.
235. Chen Z, Jalabi W, Shpargel KB, Farabaugh KT, Dutta R, Yin X et al. Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. J Neurosci 2012; 32: 11706–11715.
236. Chen Z, Jalabi W, Hu W, Park HJ, Gale JT, Kidd GJ et al. Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain. Nat Commun 2014; 5: 4486.
237. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N et al. Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530: 177–183.